Ascendis Pharma (ASND) Receives a Hold from TD Cowen

TD Cowen analyst Yaron Werber maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $156.00. The company’s shares closed yesterday at $124.82.

Werber covers the Healthcare sector, focusing on stocks such as BeiGene, Amgen, and Ionis Pharmaceuticals. According to TipRanks, Werber has an average return of 16.8% and a 54.68% success rate on recommended stocks.

In addition to TD Cowen, Ascendis Pharma also received a Hold from Oppenheimer’s Leland Gershell in a report issued on May 6. However, yesterday, Bank of America Securities maintained a Buy rating on Ascendis Pharma (NASDAQ: ASND).

The company has a one-year high of $161.00 and a one-year low of $83.75. Currently, Ascendis Pharma has an average volume of 333.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ascendis Pharma (ASND) Company Description:

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.